Maccura Biotechnology Financials
| 300463 Stock | 12.35 0.11 0.90% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 651 M | 519.2 M |
|
|
Maccura | Select Account or Indicator |
Understanding current and past Maccura Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Maccura Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in Maccura Biotechnology's assets may result in an increase in income on the income statement.
Please note, the presentation of Maccura Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Maccura Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Maccura Biotechnology's management manipulating its earnings.
Maccura Biotechnology Stock Summary
Maccura Biotechnology competes with Guangxi Wuzhou, Xiamen Jihong, Wuhan Yangtze, Great Sun, and Shanghai Ziyan. Maccura Biotechnology is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE1000020H3 |
| Business Address | Hi-tech Zone, Chengdu, |
| Sector | Life Sciences Tools & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.maccura.com |
| Phone | 86 28 8173 1888 |
You should never invest in Maccura Biotechnology without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Maccura Stock, because this is throwing your money away. Analyzing the key information contained in Maccura Biotechnology's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Maccura Biotechnology Key Financial Ratios
Maccura Biotechnology's financial ratios allow both analysts and investors to convert raw data from Maccura Biotechnology's financial statements into concise, actionable information that can be used to evaluate the performance of Maccura Biotechnology over time and compare it to other companies across industries.| Revenue | 2.9 B | ||||
| Gross Profit | 1.46 B | ||||
| EBITDA | 613.34 M | ||||
| Net Income | 312.62 M | ||||
| Total Asset | 8.12 B |
Maccura Biotechnology Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 6.4B | 6.6B | 8.2B | 8.1B | 9.3B | 5.4B | |
| Other Current Liab | 255.0M | 189.9M | 171.5M | 10.0M | 11.5M | 10.9M | |
| Other Liab | 149.8M | 231.9M | 270.7M | 248.0M | 285.2M | 299.5M | |
| Retained Earnings | 2.9B | 3.6B | 4.0B | 3.8B | 4.4B | 2.5B | |
| Accounts Payable | 402.1M | 317.4M | 380.9M | 365.8M | 420.7M | 244.9M | |
| Cash | 612.1M | 637.2M | 587.3M | 836.0M | 961.4M | 487.8M | |
| Other Assets | 225.8M | 327.2M | 336.5M | 342.8M | 394.3M | 414.0M | |
| Long Term Debt | 329.7M | 424.1M | 285.8M | 162.5M | 186.9M | 240.5M | |
| Net Receivables | 2.0B | 1.9B | 2.1B | 1.8B | 2.0B | 1.6B | |
| Inventory | 1.1B | 1.1B | 1.0B | 907.5M | 1.0B | 775.1M | |
| Other Current Assets | 235.8M | 195.8M | 251.9M | 112.6M | 129.5M | 175.1M | |
| Total Liab | 2.4B | 2.0B | 1.6B | 1.5B | 1.7B | 1.5B | |
| Intangible Assets | 245.6M | 280.8M | 374.5M | 420.8M | 483.9M | 508.1M | |
| Common Stock | 557.7M | 557.1M | 556.5M | 612.5M | 704.3M | 524.6M | |
| Net Tangible Assets | 3.0B | 3.6B | 4.1B | 5.9B | 6.8B | 3.5B | |
| Short Long Term Debt | 921.5M | 530.6M | 248.1M | 144.6M | 166.3M | 158.0M | |
| Total Current Assets | 4.0B | 3.9B | 4.7B | 4.2B | 4.9B | 3.6B | |
| Net Debt | 752.1M | 941.3M | 639.2M | 317.5M | 285.7M | 476.0M | |
| Net Invested Capital | 5.0B | 5.3B | 6.8B | 6.7B | 7.7B | 5.6B | |
| Net Working Capital | 2.2B | 2.5B | 3.6B | 3.1B | 3.6B | 2.6B | |
| Capital Stock | 557.7M | 557.1M | 556.5M | 612.5M | 704.3M | 633.3M |
Maccura Biotechnology Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 68.2M | 59.3M | 35.1M | 33.5M | 38.6M | 28.5M | |
| Total Revenue | 3.7B | 4.0B | 3.6B | 2.9B | 3.3B | 2.5B | |
| Operating Income | 1.1B | 1.3B | 894.9M | 451.5M | 519.2M | 651.0M | |
| Cost Of Revenue | 1.7B | 1.7B | 1.7B | 1.3B | 1.5B | 1.1B | |
| Income Before Tax | 969.8M | 1.2B | 789.1M | 305.4M | 351.2M | 593.2M | |
| Net Income | 793.9M | 956.6M | 708.0M | 312.6M | 359.5M | 481.8M | |
| Income Tax Expense | 127.5M | 148.4M | 184.9M | 87.7M | 100.8M | 102.7M | |
| Research Development | 202.1M | 207.3M | 273.2M | 324.2M | 372.8M | 391.4M | |
| Gross Profit | 2.0B | 2.3B | 2.0B | 1.6B | 1.8B | 1.6B | |
| Ebit | 759.8M | 1.0B | 1.2B | 894.9M | 1.0B | 802.6M | |
| Minority Interest | 208.7M | (45.6M) | 6.6M | 7.9M | 7.1M | 6.8M | |
| Tax Provision | 148.4M | 184.9M | 87.7M | 689.9K | 620.9K | 589.9K | |
| Net Interest Income | (65.5M) | (55.7M) | (23.6M) | (24.4M) | (22.0M) | (23.1M) | |
| Interest Income | 4.3M | 5.0M | 12.0M | 10.0M | 11.5M | 12.1M | |
| Ebitda | 916.0M | 1.2B | 1.5B | 1.1B | 1.3B | 1.1B |
Maccura Biotechnology Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Maccura Biotechnology. It measures of how well Maccura is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Maccura Biotechnology brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Maccura had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Maccura Biotechnology has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 501.3M | 601.8M | 987.7M | 877.9M | 1.0B | 1.1B | |
| Net Income | 793.9M | 956.6M | 708.0M | 312.6M | 359.5M | 481.8M | |
| Dividends Paid | 105.4M | 237.3M | 318.4M | (244.6M) | (281.3M) | (267.3M) | |
| Change To Inventory | (240.9M) | (19.2M) | 15.2M | 11.1M | 12.8M | 13.4M | |
| Investments | (5M) | (87.5M) | (709.7M) | (503.0M) | (452.7M) | (430.1M) | |
| Change In Cash | 152.8M | 33.0M | (51.4M) | 247.1M | 284.1M | 298.3M | |
| Net Borrowings | 310.3M | (183.1M) | (352.2M) | (291.5M) | (262.4M) | (249.3M) | |
| Depreciation | 205.2M | 235.1M | 270.2M | 313.1M | 360.0M | 186.5M | |
| Change To Netincome | 154.3M | 144.9M | 164.3M | 111.4M | 128.1M | 107.9M | |
| End Period Cash Flow | 582.6M | 615.7M | 564.3M | 811.4M | 933.1M | 527.5M | |
| Free Cash Flow | 592.7M | 1.0B | (144.5M) | 23.6M | 27.1M | 25.8M | |
| Other Non Cash Items | 76.2M | 64.8M | 33.9M | 37.2M | 42.7M | 55.5M |
Maccura Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Maccura Biotechnology's current stock value. Our valuation model uses many indicators to compare Maccura Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Maccura Biotechnology competition to find correlations between indicators driving Maccura Biotechnology's intrinsic value. More Info.Maccura Biotechnology Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.45 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Maccura Biotechnology Co is roughly 2.21 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Maccura Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Maccura Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Maccura Biotechnology Systematic Risk
Maccura Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Maccura Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on Maccura Biotechnology correlated with the market. If Beta is less than 0 Maccura Biotechnology generally moves in the opposite direction as compared to the market. If Maccura Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Maccura Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Maccura Biotechnology is generally in the same direction as the market. If Beta > 1 Maccura Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Maccura Biotechnology Co Total Assets Over Time
Maccura Biotechnology Thematic Clasifications
Maccura Biotechnology Co is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Maccura Biotechnology January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Maccura Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Maccura Biotechnology Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Maccura Biotechnology Co based on widely used predictive technical indicators. In general, we focus on analyzing Maccura Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Maccura Biotechnology's daily price indicators and compare them against related drivers.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 7.95 | |||
| Value At Risk | (3.18) | |||
| Potential Upside | 2.65 |
Complementary Tools for Maccura Stock analysis
When running Maccura Biotechnology's price analysis, check to measure Maccura Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maccura Biotechnology is operating at the current time. Most of Maccura Biotechnology's value examination focuses on studying past and present price action to predict the probability of Maccura Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maccura Biotechnology's price. Additionally, you may evaluate how the addition of Maccura Biotechnology to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |